Unknown PHASE4 INTERVENTIONAL 2-arm NCT04415918

Bezlotoxumab Efficacy and Tolerability in Cancer Patient

Is Bezlotoxumab Effective, Tolerable and Cost Saving in Preventing Recurrent Clostridium Difficile Infections in Patients With Malignancies? An Exploratory Study

Sponsor: The Cooper Health System

Conditions Clostridium Difficile Infection Recurrence

Interventions Bezlotoxumab Injection

Updated 5 times since 2020 Last updated: Jun 1, 2020 Started: Jul 1, 2020 Primary completion: Jul 1, 2021 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04415918, this PHASE4 trial focuses on Clostridium Difficile Infection Recurrence and remains ongoing. Sponsored by The Cooper Health System, it has been updated 5 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jul 2022 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Jul 2022 [monthly]

Not Yet Recruiting PHASE4
Jul 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Cooper Health System

Data source: The Cooper Health System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.